Amphastar Pharmaceuticals, Inc. (AMPH)
| Previous Close | 44.22 |
| Open | 44.23 |
| Bid | 45.11 x 100 |
| Ask | 45.24 x 100 |
| Day's Range | 44.23 - 45.27 |
| 52 Week Range | 36.56 - 65.92 |
| Volume | |
| Avg. Volume | 355,468 |
| Market Cap | 2.169B |
| Beta (5Y Monthly) | 0.82 |
| PE Ratio (TTM) | 14.99 |
| EPS (TTM) | 3.01 |
| Earnings Date | Feb 26, 2025 - Mar 03, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 58.20 |
ACCESSWIREAmphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the ...
TipRanksAmphastar initiated with an Equal Weight at Wells Fargo
Wells Fargo initiated coverage of Amphastar (AMPH) with an Equal Weight rating and $55 price target The firm likes the setup heading into 2025, saying Amphastar could have 2-3 new launches over the next 12 months, “yet is trading as if there is no pipeline.” Amphastar has a solid commercial business and just a few pipeline wins could drive long-term growth, the analyst tells investors in a research note. Wells sees 20% upside in the shares as the company enters a new product cycle. Published fir
